Scientific Program

Print
Thursday, May 14, 2015
Hall A
14:30-16:00
 
14:30-14:40
Time- lapse technology. What is the goal and what are the differences between the technologies?
Chairpersons: Klaus Diedrich, Germany; Andreas Schmutzler, Germany; Zeev Shoham, Israel
14:40-15:00
15:00-15:20
15:20-15:40
15:40-16:00
Laboratory aspects - Simon Fishel, UK
Clinical aspects - Milton Leong, HK
Dark field technology - Jon Aizpurua, Spain
Pitfalls related to the technology - Norbert Gleicher, USA

16:00-16:30

Coffee Break
Hall A
16:30-18:00
Debate: New recombinant FSH on the market: views from the experts
Chairpersons: Klaus Diedrich, Germany; Andreas Schmutzler, Germany; Zeev Shoham, Israel
16:30-17:00
 
17:00-17:30
 
17:30-18:00
Molecular aspects and background
Hermann Allgaier, Germany

Clinical Perspective

Klaus Diedrich, Germany

Supporting the current available recombinant FSH

Klaus Bühler, Germany
18:00-19:00
Are we reaching the time when science meets wishful thinking?
Chairpersons: Robert Fischer, Germany; Norbert Gleicher, USA
18:00-18:30 Autologous mitochondrial injection to increase energy in oocytes
Robert Casper, Canada
18:30-19:00 Non-invasive prenatal diagnosis from the blood of pregnant women- finally available in clinical practice
Wolfgang Holzgreve, Germany
19:00-20:00
Welcome Reception

Friday, May 15, 2015
Hall A
08:30-10:30
New innovation in Cryobiology
Chairpersons: Robert Casper, Canada; Claus Yding Andersen, Denmark
 
 
08:30-09:00
09:00-09:30
Debate: Social freezing of oocytes and ovarian tissue to maintain fertility and postpone menopause: low cost, easy administration and good outcome. Is it such?
For: Claus Yding Andersen, Denmark
Against: Michael von Wolff, Switzerland
09:30-10:00
Pregnancies and live births after 20 transplantations of cryopreserved ovarian tissue: The technology is now available for all
Ralf Dittrich, Germany
10:00-10:30 Oocyte cryopreservation for fertility preservation in cancer patients – how good is it? If you have one go and perhaps a reduced response due to sickness, what should be the stimulation protocol?
Kenny Rodriguez-Wallberg, Sweden

in parallel

Hall B
08:30-10:30
New innovation in Genetics
Chairpersons: Wolfgang Holzgreve, Germany; Yuval Yaron, Israel
08:30-09:00 Individual preparation of the ovaries for PGD or PGS
Andreas Schmutzler, Germany
 
09:00-09:15
09:15-09:30
Debate: Should PGS be offered to all IVF patients?
Pro: Simon Fishel, UK
Con: PGS: Norbert Gleicher, USA
09:30-10:00
Polar body biopsy: new aspects
Luca Gianaroli, Italy
10:00-10:30 How next-generation sequencing revolutionized reproductive medicine
Yuval Yaron, Israel

10:30-11:00

Coffee Break
Hall A
11:00-12:30
Getting the best pregnancy rate: stimulation and ET
Chairpersons: Ramon Aurell, Spain; Salim Daya, Canada; Olaf Naether, Germany
11:00-11:25
IVF outcomes in patients with extremely poor prognosis
Ariel Weissman, Israel
11:25-11:50
Treating infertile premature ovarian insufficiency (POI) patients: ovarian fragmentation followed by Akt stimulation treatment in vitro and autotransplantation (in vitro activation – IVA)
Kazuhiro Kawamura, Japan
11:50-12:15
GnRH agonist triggering oocyte maturation for all ART cycles: Four years' experience and results
Robert Fischer, Germany
12:15-12:30 New metallic spiral outer Catheter for Difficult Embryo Transfer
Hans-Peter Steiner, Austria

in parallel

Hall B
11:00-12:30

Laparoscopy in infertility
Chairpersons: Sara Brucker, Germany; Bernhard Krämer, Germany; Florin-Andrei Taran, Germany

11:00-11:30 
Surgical therapy of deep infiltrating endometriosis: state of the art and limitations
Bernhard Krämer, Germany
11:30-12:00 Adenomyosis: a neglected disease?
Florin-Andrei Taran, Germany
12:00-12:30 Live streaming of two surgical procedures on endometriosis

Ralf Rothmund, Germany
Diethelm Wallwiener, Germany

12:30-13:30

Lunch Break
Hall A
13:30-15:30
Getting the best pregnancy rate: stimulation and ET (2)
Chairpersons: David Barad, USA; Salim Daya, Canada

13:30-14:00
14:00-14:30
Debate: Neoadjuvants in stimulation protocols: what can we add?
For: Gürkan Uncu, Turkey
Against: Narmada Katakam, UK
14:30-15:00
Differed embryo transfer (DET) is bound to improve outcomes. Should we cryopreserve all embryos?
Anna Raggi, Switzerland
15:00-15:30 Subclinical hypothyroidism is a major cause of infertility in women
George J. Kahaly, Germany

in parallel

Hall B
13:30-15:30
Regenerative medicine and ART for clinicians
Chairpersons: Simon Fishel, UK; Rajiv Mahendru, India; Monica Tobler, Germany
Capsule: How might stem cells and regenerative insights contribute to IVF, fertility preservation, implantation failures and aging patients? If not now, when?
13:30-14:00
Origin of the stem cell types in the human ovary
Outi Hovatta, Sweden
14:00-14:30
Germ line stem cells
Evelyn Telfer, UK
14:30-15:00
IVM: finalizing the best protocol for the procedure
Seang Lin Tan, Canada
15:00-15:30
"Burning out" PCOS patients
Norbert Gleicher, USA

15:30-16:00

Coffee Break
Hall A
16:00-18:00
New innovations in Biomarkers development and implantation
Chairpersons:Norbert Gleicher, USA; Ariel Weissman, Israel
16:00-16:30 AMH, FSH and AFC: can these markers guide us in cases of ovarian cysts and endometriosis surgery?
Ludwig Kiesel, Germany
16:30-17:00 G-CSF: does it add real value to IVF success?
Norbert Gleicher, USA
17:00-17:30
Mechanical irritation of the endometrium: is this the answer?
Salim Daya, Canada

in parallel

Hall B
16:00-18:00
Cross-border embryo transportation
Chairpersons: Meenu Agarwal, India; Martha Direnfeld, Israel
16:00-16:30
Cross-border transportation of fresh embryos: is it viable?
Clinical and Laboratory overview: David Bider, Israel
16:30-17:00
Is the vaginal mucosa the best route to administer steroids to treat endometriosis?
Hugo Maia Jr, Brazil
Optimal approach to adenomyosis and endometriosis treatment
17:00-17:30
Adenomyosis: the optimal approach
Umit Inceboz, Turkey

Saturday, May 16, 2015
Hall A
08:30-10:30
Embryo evaluation and luteal support
Chairpersons: Attila Vereczkey, Hungary; Shahar Kol, Israel
08:30-09:00
 
09:00-09:30
 
 
 
09:30-10:00
 
10:00-10:30
The 3D embryo evaluation: a dream turned into a reality
Samir Hamamah, France
Innovative luteal phase support: new options for enduring challenges
Luteal phase support (LPS) is necessary in all forms of controlled ovarian stimulation (COS) cycles. What drugs are needed and how can they be delivered using better physiological methods
Dominique de Ziegler, France
Luteal phase support: dose ranging issues
Christian De Geyter, Switzerland
Luteal coasting post GnRH agonist trigger
Shahar Kol, Israel

10:30-11:00

Coffee Break
Hall A
11:00-13:00
Innovation in treatment protocols
Chairpersons: Klaus Diedrich, Germany; Andreas Schmutzler, Germany; Zeev Shoham, Israel
 
 
11:00-11:30
11:30-12:00
12:00-12:30
 
12:30-13:00
Debate: Natural cycle and minimal stimulation: is it a realistic approach or should it be abandoned?
Pro: Thomas Strowitzki, Germany
Con: David Barad, USA
Double stimulation: should this be a routine procedure in poor responders? Is it a possible solution?
Dominique de Ziegler, France
Metformin: a treatment for all patients undergoing infertility treatment?
David Barad, USA